Article3 Biotech2025
Triple regulation of oxidative-acetylation cycling pathways in COPD glucocorticoid resistance by HuaTanJiangQi capsules.
Article in 3 Biotech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- 4-Hydroxynonenal, a Potential Biomarker for Lung Inflammatory Diseases.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glucocorticoid (GC) resistance in chronic obstructive pulmonary disease (COPD) induced by long-term smoking, significantly reduces the quality of life of patients. The complex interaction between antioxidants and acetylation is an important factor that contributes to the slow progression of treatment. This study highlights the development of GC resistance in COPD through 4-hydroxynonenal (4-HNE), multidrug resistance-associated protein 1 (MRP1), histone deacetylase 2 (HDAC2), and nuclear related factor 2 (Nrf2), using enzyme-linked immunosorbent assays, western blotting, and siRNA silencing. Our results suggest that long-term exposure to cigarette smoke can increase 4-HNE toxicity via reactive oxygen species (ROS)-induced lipid peroxidation and decrease the expression of MRP1, histone HDAC2, and Nrf2. Together, these molecules form and enhance the cyclic resistance pathway in COPD, including MRP1 reducing 4-HNE efflux, 4-HNE down-regulating HDAC2 expression by oxidation, HDAC2 reducing Nrf2 transcription by deacetylation, and Nrf2 reducing MRP1 expression through acetylation. The HuaTanJiangQi Capsule (HTJQ) reduces GC resistance via a triple regulatory pathway by enhancing the activity of HDAC2, promoting the transcription of Nrf2, up-regulating the expression of MRP1, and reducing lipid peroxidation induced by ROS. Thus, this cyclic mechanism of GC resistance in COPD may open new avenues for robust therapies using HTJQ.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.